Evotec/Haplogen collaborate to develop drugs for viral diseases


Evotec and Haplogen have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Under the agreement, Haplogen and Evotec will co-develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen's powerful proprietary technology to identify host factors for infectious human pathogens. Evotec will further develop Haplogen's lead compounds and apply its drug-discovery platform to find additional small-molecule inhibitors. Terms of the partnership were not disclosed.



Agreement Information:
Agreement Status: New Date Announced: 15 Nov 2012
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Development
Generic / Brand Name:
Therapeutic Area: General Anti-infectives Systemic
Indication: Viral infections
Techonology/Field: Drug development Drug discovery



Agreement Information:
Agreement Status: New Date Announced: 15 Nov 2012
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Development
Generic / Brand Name:
Therapeutic Area: General Anti-infectives Systemic
Indication: Viral infections
Techonology/Field: Drug development Drug discovery
This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Austria, Austria, Germany, Austria, Austria